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Abstract 
Background: Previous studies on breast cancer (BC), underarm cosmetic products (UCP) and 
aluminum salts have shown conflicting results. We conducted a 1:1 age-matched case-control 
study to investigate the risk for BC in relation to self-reported UCP application. 
Methods: Self-reported history of UCP use was compared between 209 female BC patients 
(cases) and 209 healthy controls. Aluminum concentration in breast tissue was measured in 
100 cases and 52 controls. Multivariable conditional logistic regression analysis was 
performed to estimate odds ratios (ORs) with 95% confidence intervals (CIs), adjusting for 
established BC risk factors.  
Findings: Use of UCP was significantly associated with risk of BC (p=0.036). The risk for 
BC increased by an OR of 3.88 (95% CI 1.03-14.66) in women who reported using UCP's 
several times daily starting at an age earlier than 30 years. Aluminum in breast tissue was 
found in both cases and controls and was significantly associated to self-reported UCP use 
(p=0.009). Median (interquartile) aluminum concentrations were significantly higher 
(p=0.001) in cases than in controls (5.8, 2.3-12.9 versus 3.8, 2.5-5.8 nmol/g). 
Interpretation: Frequent use of UCPs may lead to an accumulation of aluminum in breast 
tissue. More than daily use of UCPs at younger ages may increase the risk of BC.  
 
Key words: underarm cosmetic products, aluminum, breast cancer, case-control study, 
epidemiology 
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Highlights 
 Frequent use of underarm cosmetic products may be related to incorporated aluminum 
concentration in breast tissue.  
 Use of underarm cosmetic products several times a day at younger ages may increase 
the risk of breast cancer. 
 
Research in context  
Previous studies regarding breast cancer (BC) risk and underarm cosmetic products (UCPs) 
with aluminium salts have shown conflicting results. Here we provide comprehensive 
information about the use of UCPs and aluminum measurements in breast cancer patients and 
healthy individuals. The findings suggest that the frequent use of UCPs lead to an 
accumulation of aluminum in breast tissue. We observed an increased risk for BC in women 
who reported to use UCPs more than once daily starting at an age <30 years. We recommend 
that particularly women at younger ages should be careful using UCPs and avoid its excessive 
use.  
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Background 
Breast cancer is the most common cancer in women with a high prevalence in economically 
developed countries (Kristensen et al., 2014; Parkin et al., 2005). The etiology of breast 
cancer is multifactorial. Age, genetic mutations and life-time estrogen exposure are well 
known risk factors (Gail and Pfeiffer, 2015; Petracci et al., 2011; Pfeiffer et al., 2013). These 
factors explain only a small part of the etiology (Turnbull and Rahman, 2008) suggesting that 
environmental factors may also be relevant in the development of breast cancer (Bonefeld-
Jorgensen et al., 2011; Coyle, 2004). A change in the topological distribution of mammary 
carcinoma since 1975 (Bright et al., 2016; Darbre, 2016, 2009, 2005, 2003) towards an higher 
incidence in the upper outer quadrant seems to point to underarm cosmetic products (UCPs) 
as a potential contributor (Darbre, 2009, 2005, 2003; Darbre et al., 2013b). Previous studies 
investigating the effect of UCPs on breast cancer have shown conflicting results (McGrath, 
2003; Mirick et al., 2002; Pasha et al., 2008; Rodrigues-Peres et al., 2013). Therefore, latest 
systematic reviews were not able to provide conclusive evidence (Namer et al., 2008; Willhite 
et al., 2014). Active ingredients in most UCPs are aluminum-based compounds as aluminum 
chloride and aluminum chlorohydrate. Aluminum salts have been associated with oxidative 
stress, DNA double strand breaks, proliferation, interference in estrogen action before 
(Darbre, 2009; Darbre et al., 2013a; Dyrssen et al., 1987; Farasani and Darbre, 2015; Lankoff 
et al., 2006; Sappino et al., 2012) and with metastasis recently (Mandriota et al., 2016). 
Mandriota et al. (2016a) demonstrated in an established cancer mouse model that 
concentrations of aluminum in the range of those measured in human breast are able to 
transform cultured mammary epithelial cells, enabling them to form tumors and to 
metastasize. It was further suggested that frequent use of UCPs containing aluminum salts is a 
main source of measured aluminum in breast structures (Darbre et al., 2013b, 2011; Exley et 
al., 2007; Mannello et al., 2009). Due to the genotoxic and possibly carcinogenic effect of 
aluminum salts, the use of UCPs may be related to breast cancer (Darbre, 2001; Jennrich and 
Schulte-Uebbing, 2016; Pineau et al., 2014; Rodrigues-Peres et al., 2013; Sappino et al., 
2012). 
The relationship of UCPs containing aluminum salts with breast cancer was investigated in  
few epidemiological studies showing conflicting results (Fakri, 2006; McGrath, 2003; Mirick 
et al., 2002). Mirick et al. (2002)  and Fakri (2006)) found no significant associations between 
antiperspirants and increased risk of breast cancer. In contrast, McGrath, (2003)  found that 
patients using UCPs frequently received their breast cancer diagnosis at an earlier age than 
patients avoiding UCPs. However, none of these studies included breast tissue measurements 
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of aluminum with regard to UCP use. There exists, so far, no controlled study investigating 
the relationship of aluminum with breast cancer combining an epidemiologic approach with 
breast tissue measurements. 
We conducted a 1:1 age-matched hospital-based case-control study aiming to investigate the 
risk for breast cancer in relation to self-reported UCP use. We included measurements of 
aluminum concentrations in breast tissue from a large series of breast cancer patients and 
healthy individuals in a controlled epidemiologic study. We hypothesized that (1) breast 
cancer patients had used UCPs more frequently during their lives than healthy controls, that 
(2) aluminum concentrations in breast tissue is increased in cases, and that (3) there is a 
relationship between UCP use and measured aluminum concentrations in breast tissue. 
 
Methods 
Study design and participants 
Participants of this age-matched case-control study were recruited between January 2013 and 
October 2016 at the Medical University of Innsbruck, Austria.  Eligible cases were all breast 
cancer patients aged 20–85 years treated by the Department of Obstetrics and Gynecology 
who had a confirmed diagnosis of breast cancer within the last 5 years. Eligible controls were 
women in the same age range (±2.5 years) without a history of malignant breast disease. 
Controls were recruited either at the Department of Plastic, Reconstructive and Aesthetic 
Surgery or at other departments. Selection of controls did not follow a formal probability 
sampling scheme. Because of organizational limitations sampling was done on random time 
points when trained interviewers were available to find voluntary women fulfilling the 
inclusion criteria. Cases undergoing mastectomy and healthy controls undergoing reduction 
mammoplasty were eligible for tissue sampling.  
The study was approved by the ethics committee of the Medical University of Innsbruck, 
(UN4759, 315/4.6). All participants provided their written informed consent before taking 
part in the study. 
 
Data source and tissue samples 
Structured personal interview 
A structured personal interview was performed with all study participants by interviewers 
who were trained to avoid suggestive questions and to use the key words antiperspirants, 
deodorants and aluminum very carefully. The interviewers were medical school students in 
their last year and a graduated psychologist. The questionnaire used in these interviews was a 
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modified version of the validated questionnaire used in the MARIE study (Slanger et al., 
2007). We collected information on participant characteristics, lifestyle factors including 
nutrition and alcohol, estrogen and hormone exposure as well as genetic factors. Questions 
asked refer to past exposure in four lifetime categories: ‘under the age of 30 years’, ‘between 
30 and 50 years’, ‘over the age of 50 years’ and ‘last five years before breast cancer 
diagnoses’. We extended this questionnaire by specific questions regarding personal hygiene, 
UCP use and aluminum exposure. The majority of UCPs on the market during the past years 
were antiperspirants containing aluminum salts as active ingredients. There are a few UCPs 
without aluminum salts commonly called “deodorants” containing ingredients such as 
perfumes and etheric oils. When asked it turned out that most women were not able to 
discriminate between these two kinds of UCPs. We therefore concluded that it would be 
misleading to analyze antiperspirants and deodorants separately and consequently 
summarized them into the term UCP as the main exposure variable. UCP application 
categorized in “never”, “1-4 times per month”, “2-6 times per week”, “daily” and “several 
times per day” was defined as the primary endpoint of this study.  
 
Tissue sampling and measurement 
Tissue sampling was performed in all cases and controls undergoing surgery. In cases, we 
took samples of the breast affected by the tumor, in controls sampling was performed on both 
breasts. Samples of 500mg were collected near the axilla in the upper outer quadrant, near the 
mammilla and near the lateral sternal edge in the lower inner quadrant. Thus, we collected 
three samples in cases and six samples in controls. 
In cases, breast tissue was sampled at the day of surgery at the Morphology Laboratory of the 
Department of Obstetrics and Gynecology during preparation for macroscopic and histo-
pathological analysis. In controls, tissue sampling was performed during the breast reduction 
surgery in the operation theatre of the Department of Plastic, Reconstructive and Aesthetic 
Surgery. Samples were carefully collected avoiding any background contamination with 
aluminum regarding the use of surgical instruments, lab tools and vials. Samples were 
labelled with a patient code blinding any information regarding case/control assignment and 
tissue location and were immediately frozen and stored at -80°C at the Department of 
Biochemistry until analysis. Tissue preparation and defatting was conducted as described in 
Exley et al., (2007). In brief, thawed tissue was defatted by incubation at 37°C for maximal 72 
hours to assure that dried tissue achieved constant weight. Mean of wet weight of samples 
was 400 mg (±100 mg), mean of dried tissue was 150 mg (±100 mg). Fat was released as 
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clear oil during drying process in inclined plastic weighing boats. For degreasing and tissue 
transfer we only used metal free instruments. Dry, weighed and defatted tissue was transferred 
into 20 mL PFA Teflon© vessels with venting plugs and screw caps (CEM Microwave 
Technology, Germany). Further tissue preparation, digestion and dilution was done according 
to House et al., 2013.  For digestion we used high quality Nitric acid 69% Trace SELECT® 
(Sigma-Aldrich, Germany). Digested and diluted tissue samples as well as ninety method 
blanks were analyzed as clear fluids with graphite furnace atomic absorption spectrometer 
(GF-AAS) with Zeeman–effect background corrector (Thermo Scientific, Germany).   
 
Statistical Analysis 
The sample size of this case-control study was pre-specified and determined to be adequate to 
detect an odds ratio (OR) of 2 or greater for UCP application on a significance level of 5%.  
Assuming a control proportion of 65% UCP use as in Mirick et al., (2002), to achieve 80% 
statistical power, we were aiming to recruit 200 participants per group, a total of 400 women. 
In total we recruited 460 participants, 210 cases and 250 controls. Each case was age-matched 
in a 1:1 ratio to one control subject, minimizing the age difference within case-control pairs 
by a validated matching algorithm. The application of this algorithm ensured an objective and 
random assignment of cases to controls in order to reach the optimum result in terms of age 
difference. Consequently, the pairs differed regarding interview dates.   
Patient characteristics, genetic factors, hormone exposure, life style parameters, UCP use 
were compared between cases and controls using descriptive statistics. Means and medians as 
well as standard deviations (SD) and interquartile ranges (IQR) were calculated to summarize 
continuous variables. Categorical variables were presented as frequencies and percentages. 
We conducted conditional logistic regression analyses to determine relative risks, estimated as 
odds ratios (ORs) with 95% confidence intervals (CI) for UCP application and other 
exposures related to breast cancer. The final multivariable model included all variables that 
showed a p-value < 0.25 in univariable analyses as well as all relevant variables knowing to 
be associated with breast cancer (Pfeiffer et al., 2013). We assessed effect modification 
through tumor localization and timing of interviews by including interaction terms into the 
adjusted conditional logistic regression models. 
Aluminum concentrations from the different sampling locations (three per case and six per 
control) were averaged per women, summarized with medians and interquartile ranges (IQR) 
for cases and controls and stratified by UCP application. In a first step, the summarized 
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aluminum concentrations were compared between cases and controls with an independent t-
test. In a second step, a three-way ANOVA for repeated measurements with the between-
subject factor ‘case versus control’, ‘UCP use’ as ordinal scaled covariate, and the within-
subject factor ‘sampling location’ was performed on log10(x+1) aluminum concentrations. 
We performed subgroup analysis for aluminum measurements separately for cases with 
tumors in the upper outer quadrant and tumors in other quadrants. We considered a p-value 
smaller than 0.05 as statistically significant. For both matching and statistical analysis SPSS 
Statistics v.22 (IBM Analytics, Armonk, NY, USA) was used. 
 
Results 
A total of 460 women participated in this study, of these 210 were breast cancer cases and 250 
were healthy controls. We excluded one case due to breast cancer diagnosis earlier than 5 
years before the interview. One control had to be excluded due to unclear breast tissue 
pathology. Finally, 209 cases were matched 1:1 to 209 controls minimizing the age 
differences within pairs to a maximum of 3.5 years. Consequently cases and controls did not 
differ regarding mean age (51.9 ± 12.0 versus 51.8 ± 12.1). Tissue samples were available in 
100 cases and 52 controls undergoing surgery.  
Characteristics of breast cancer patients and healthy controls together with crude ORs from 
univariable analyses are shown in Table 1. As expected positive family history of breast 
cancer was the most pronounced risk factor. Further characteristics that were significantly 
different between cases and controls were a family history of other cancers such as prostate, 
ovarian and endometrium cancer, history of benign breast disease and a lower body mass 
index.  
As shown in Table 2, self-reported use of UCP at early ages (< 30 years) was significantly 
associated with an increased risk of breast cancer (p=0.0358) adjusting for age, family history 
of breast cancer, family history of other cancer, history of benign breast disease, age at 
menarche, parity, age at birth of first child, age at menopause, menopausal status, hormone 
replacement therapy, average body mass index and alcohol consumption. This association was 
triggered by women who reported that they had used UCPs several times per day under their 
age of 30 increasing their risk for breast cancer by an OR of 3.88 with a 95% CI of 1.03-14.66 
(p=0.0456).  
Aluminum in breast tissue (Table 3) was found in both cases and controls ranging from 0 to 
367.38 nmol/g dry weight and was significantly associated with self-reported UCP use 
(p=0.0269 for UCP use under the age of 30, p=0.0093 for UCP use during the last 5 years). In 
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cases, median (interquartile) aluminum concentrations observed were 5.8 (2.3-12.9) nmol/g, 
significantly higher (p=0.0014) than in controls (3.8, 2.5-5.8 nmol/g).  
In addition, we analyzed whether tumor localization modifies the relationship between self-
reported UCP use, aluminum concentration and the risk for BC. Regarding UCP use there was 
no significant effect modification by tumor localization (p=0.680 for the UCP use <30 years 
model, p=0.341 for the UCP use during last 5 years). In contrast, regarding measured 
aluminum concentrations, the stratified results for tumor localization showed significant 
differences between cases and controls in the subgroup of cases with a tumor in the upper 
outer quadrant only (Table 4). 
 
Discussion 
The findings of this age-matched hospital based case-control study suggest an association 
between UCP use, aluminum concentration in breast tissue and breast cancer. We found a 
significant difference between cases and controls in the pre-specified primary endpoint. 
However, the observed association of UCP use with breast cancer was in fact limited to 
women who reported using UCP's several times a day when they were under the age of 30.  
In contrast to our findings, previous epidemiologic studies (Fakri, 2006; Mirick et al., 2002)  
did not support the hypothesis that UCP use increases the risk for breast cancer. Fakri, (2006) 
examined a very small sample of 54 unmatched cases and 50 controls underpowered to detect 
realistic effect sizes. In their study UCP use was dichotomous categorized in just two levels, 
using of UCPs versus no use, which is too imprecise in regard to our results, where a 
significant association was observed only when women used UCPs several times per day. 
Similarly, in the much larger study of Mirick et al., (2002), UCP use was measured also in a 
dichotomous way only. In the study of Mirick et al., (2002) study participants were not asked 
about UCP use in different life time categories and therefore possible effects of UCP use at 
younger ages were not detectable. In fact, Mirick et al., (2002) reported antiperspirant use 
rather than UCP use, however, in the light of our experiences it is unclear how the authors 
discriminated between deodorant and antiperspirant use. Another important difference 
between Mirick et al., (2002) and our study exists regarding the birth cohorts of breast cancer 
patients recruited into the two studies. Breast cancer patients participating in the study of 
Mirick et al., (2002) were diagnosed in the early 1990’s, on average 20 years earlier than 
patients in our study. At the time relevant for exposure, approximately between 1940 and 
1960, the use of UCPs was less common than 20 years later. UCP use strongly increased in 
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the last four decades and also cultural habits such as shaving of axilla hair became only 
popular during the late 1980’s in western countries (Darbre, 2009, 2003; McGrath, 2003). 
So far, there exist six studies that measured aluminum concentration in breast cancer patients 
comparing concentrations between benign and malign breast tissues (Exley et al., 2007; 
House et al., 2013; Millos et al., 2009; Ng et al., 1997; Pasha et al., 2008; Rodrigues-Peres et 
al., 2013). These studies differed considerably regarding the amount of aluminum found in 
breast tissue likely because of discrepancies in measurement techniques. Regarding, the 
analytical approach the measured aluminum concentrations in our cohort were similar to the 
studies of House et al., (2013) and Rodrigues-Peres et al., (2013). 
None of the previous studies sampled control tissue from healthy individuals. Our study 
included tissue measurements of breast cancer patients and healthy individuals observing a 
significant difference regarding aluminum concentrations. Beyond this, we were able to show 
a significant association between measured aluminum concentrations in breast tissue and self-
reported UCP use suggesting dermal absorption of aluminum salts.  
Differences in aluminum concentration between cases and controls were only evident when 
restricting the analysis to cases with tumors in the upper outer quadrant, supporting the 
hypothesis of Darbre, (2005b, 2009)  that tumors in the upper outer quadrant are affected by 
the use of UCPs. Results of the questionnaire part, however, do not support this hypothesis. 
Self-reported UCP use did not differ significantly between cases and controls when 
considering tumor localization.    
Tissue samples of controls showed less variation in aluminum concentrations than samples of 
breast cancer patients. In ten breast cancer patients, aluminum concentrations over 60 nmol/g 
up to 367 nmol/g dry weight (15-115 nmol/g wet weight) were observed. Mandriota et al., 
(2016) and colleges recently showed that aluminum salt concentrations of 100 nmol/g wet 
weight lead to transformation of in-vitro cultured mammary epithelial cells enabling them to 
form tumors and metastasis in mouse models. In contrast, aluminum concentration in controls 
reached a maximum of 24.5 nmol/g dry weight (8 nmol/g wet weight) only.  
Our study has several strengths. We combined comprehensive questionnaire data of breast 
cancer cases and healthy individuals on underarm hygiene habits with data of aluminum 
concentration in tissue samples. We applied a well-developed and accurate method for 
aluminum measurement (Exley et al., 2007; House et al., 2013). A standardized sampling 
procedure, high purity of reagents and a high measurement accuracy minimized background 
contamination. It is likely that aluminum in breast tissue has a patchy distribution (Exley et 
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al., 2007; House et al., 2013), therefore, we collected multiple tissue samples alongside the 
transect from upper outer to upper inner quadrant. 
Certain limitations of our study need to be discussed. A case-control study is susceptible to 
recall bias. Self-reporting information may be incomplete or inaccurate and may differ 
between cases and controls. Younger women may remember in more detail about their 
specific hygiene habits than elderly women. The mix of incident and prevalent cases in our 
study may be an additional source of bias. We assessed whether the time span between BC 
diagnosis and interview date is an effect modifier for the relation of UCP use with risk for 
BC. Although there is no significant effect modification of the different timing of interviews 
(p=0.282, for the ‘UCP use under the age of 30’ model, p=0.877 for the ‘UCP use in the last 5 
years’ model) we cannot rule out any recall issues between incident and prevalent cases. 
We tried to reduce reporting and measurement bias by performing personal interviews with 
well-trained interviewers. The limited sample size of the study leads to relatively small 
numbers in the sub-categories of the main exposure variable. Though significant, the result 
concerning UCP use several times per day is based on a few cases only. Furthermore, we 
cannot exclude a reverse causation effect, meaning that the breast tumor may accumulate 
aluminum. There are studies that reported higher levels of transition metals in tissue of breast 
cancer patients (Cui et al., 2007; Ionescu et al., 2006; Romanowicz-Makowska et al., 2011). 
Although, we matched cases and controls on age, the subgroup for tissue sampling is not age 
matched. However, in our study, aluminum concentrations did not correlate with age (r=-
0.028, p=0.7291). 
In conclusion, our study provides novel insights and additional evidence regarding a possible 
role of UCP use and aluminum salts in the etiology of breast cancer. Our findings suggest that 
frequent use of UCPs may lead to an accumulation of aluminum in breast tissue. We could 
even show that women who reported to use UCPs several times a day starting at an age under 
30 years may even have an increased risk for breast cancer. Until definitive answers about the 
involvement of aluminum in carcinogenesis of breast cancer, we recommend that particularly 
women at their younger ages should be careful with the use of UCPs and avoid its excessive 
use.  
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Table 1 Self-reported characteristics of breast cancer patients and healthy controls. 
 
Cases (n=209) Controls  (n=209) Crude OR (95% CI)
†
 p-value   
Age at interview [years, means (SD)] 51·9 (12·0) 51·8 (12·1)  0·2994  
Family history of breast cancer (%) 76 (36·4) 32 (15·3) 2·91 (1·81-4·68) <0·0001   
None 133 (63·6) 177 (84·7) reference     
1 person 48 (23·0) 27 (12·9) 2·21 (1·30-3·74) 0·0034   
2 or more 28 (13·4) 5 (2·4) 6·31 (2·4-6·53) 0.0002   
Family history of other cancer (%) 128 (61·5) 103 (49·3) 1·60 (1·09-2·35) 0·0176   
History of benign breast disease (%) 63 (30·1) 43 (20·6) 1·61 (1·04-2·48) 0·0326   
Age at menarche [years, means (SD)] 13·5 (1·7) 13·4 (1·5) 1·04 (0·92-1·17) 0·5547  
Menstruation (%)           
Regular 164 (78·5) 171 (81·8) reference     
Unregularly 42 (20·1) 37 (17·7) 1·19 (0·71-1·98) 0·5155   
Unknown 3 (1·4) 1 (0·5)       
Hormonal contraceptives (%) 164 (78·5) 168 (80·4) 0·87 (0·52-1·46) 0·5997   
Parity (%) 176 (84·2) 172 (82·3) 1·17 (0·68-2·01) 0·5794  
Age at birth of first child [years, means (SD)] 26·1 (5·6) 25·1 (5·3) 1·02 (0·98-1·08) 0·3838   
Lactation (%) 137 (65·6) 132 (63·5) 1·09 (0·73-1·61) 0·6861   
Lactation [months, means (SD)] 3·8 (4·5) 4·0 (5·3) 0·99 (0·95-1·03) 0·7033   
Age at menopause  47·3 (7·2) 48·6 (5·7) 0·98 (0·93-1·03) 0·2990   
Hormone replacement therapy (%) 44 (21·1) 34 (16·3) 1·42 (0·84-2·39) 0·1881  
Average body mass index [kg/m
2
, means (SD)]  22·8 (3·4) 23·4 (4·0) 0·95 (0·89-0·99) 0·038   
Smoking (%)           
Never  100 (47·8) 98 (46·9) reference     
Sometimes 20 (9·6) 28 (13·4) 0·70 (0·37-1·32) 0·2733   
regular 89 (42·6) 83 (39·7) 1·07 (0·69-1·66) 0·7586   
Alcohol consumption (%)      
0 drinks per day 29 (13·9) 29 (14·0) reference   
<=1 drink per day 172 (82·3) 175 (84·5) 1·02 (0·58-1·82) 0·9364  
1+ drink per day 8 (3·8) 3 (1·4) 2·72 (0·65-11·34) 0·1684  
 
†
 derived from univariable conditional logistic regression analysis. 
Table 2 Use of underarm cosmetic products (UCP) in breast cancer (BC) patients and healthy controls  
 
Number 
of cases 
(%) 
(n=209) 
Number of 
controls (%) 
(n=209) 
Crude OR 
(95% CI) 
Crude p-
value  
Adjusted OR
† 
(95% CI) 
Adjusted 
p-value 
UCP use in women when they were 
under the age of 30  
   0·0951  0·0358 
Never 43 (20·6) 46 (22·0) reference  reference  
1-4 times per month 19 (9·1) 26 (12·4) 
0·83 (0·40-
1·73) 
0·6222 0·50 (0·20-1·26) 0·1435 
2-6 times per week 26 (12·7) 36 (17·2) 
0·87 (0·43-
1·75) 
0·6930 0·53 (0·23-1·25) 0·1486 
Daily 103 (49·3) 89 (42·6) 
1·40 (0·79-
2·53) 
0·2603 1·03 (0·51-2·07) 0·9390 
Several times per day 18 (8·6) 9 (4·3) 
2·84 (1·02-
7·89) 
0·0451 
3·88 (1·03-
14·66) 
0·0456 
Unknown 0 (0·0) 3 (1·4)       
UCP use during last 5 years before BC diagnosis in cases / during last 5 years before 
interview in controls   
0·1104  0·0822 
Never 25 (12·0) 34 (16·3) reference  reference  
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1-4 times per month 24 (11·5) 21 (10·0) 
1·67 (0·73-
3·81) 
0·2211 1·41 (0·49-4·04) 0·5216 
2-6 times per week 31 (14·8) 45 (21·5) 
0·99 (0·49-
2·02) 
0·9824 0·59 (0·25-1·40) 0·2338 
Daily 109 (52·2) 96 (45·9) 
1·70 (0·90-
3·21) 
0·1046 1·22 (0·56-2·66) 0·6105 
Several times per day 20 (9·6) 13 (6·2) 
2·63 (1·00-
6·87) 
0·0492 
3·16 (0·90-
11·15) 
0·0736 
Unknown 0 (0·0) 0 (0·0)      
†
Adjusted for age at interview, age at menarche, parity, age at first live birth, menopausal status, age at 
menopause, MHT drug therapy, history of breast cancer, history of benign breast disease, family history of other 
cancer, BMI, alcohol consumption in multivariable conditional logistic regression analysis. 
Table 3 Median (IQR) of total aluminum concentrations [nmol/g dry weight] in breast tissue samples of 
cases and controls stratified by underarm cosmetic product (UCP) use. 
 Cases n Controls n 
p-value  
sampling 
location 
p-value  
UCP use 
p-value  
cases vs 
controls 
Median (IQR) of Al
3+ 
concentration
†
  5·77 (2·29-12·90) 100  3·77 (2·47-5·78) 52   0·0014 
UCP use in women when they were under the age of 30
‡
       
Never  3·58 (1·72-9·25) 28 2·74 (1·90-4·21) 11 
0·100 0·0344 0·0269 
Several times per week 7·77 (4·74-11·40) 9 3·07 (2·75-4·52) 4 
Daily 6·07 (2·21-14·89) 53 4·34 (2·67-6·42) 34 
Several times per day 11·29 (3·62-13·21) 9 2·51 (1·86-4·86) 3 
UCP use during last 5 years before BC diagnosis in cases / during last 5 years before interview in controls
‡
  
Never  3·58 (1·72-7·32) 20 3·32 (1·90-4·21) 10 
0·251 0·0093 0·0376 
Several times per week 7·74 (3·23-11·40) 10 3·07 (2·55-5·86) 6 
Daily 6·07 (2·34-14·89) 57 3·96 (2·54-5·99) 31 
Several times per day 12·10 (3·50-14·68) 12 4·86 (2·51-10·23) 5 
†
 Independent samples t-test with log10(x+1) transformed data. 
‡
 Three-way analysis of variance with log10(x+1) transformed data. Repeated aluminum measurements at three 
different sampling locations (upper outer, mammilla and lower inner breast quadrant) were considered as within -
subject factor in the ANOVA.  
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Table 4 Median (IQR) of total aluminum concentrations [nmol/g dry weight] in breast tissue samples of 
cases and controls stratified by underarm cosmetic product (UCP) use. Subgroup analyses for cases with 
tumors in the upper outer quadrant (Table 4a) and for cases with tumors in other quadrants (Table 4b). 
Table 4a: Tumor located in the upper outer quadrant 
 Cases n Controls n 
p-value  
sampling 
location 
p-value  
UCP use 
p-value  
cases vs 
controls 
Median (IQR) of Al
3+ 
concentration
†
  7·00 (3·10-16·15) 55  3·77 (2·47-5·78) 52   0·0003 
UCP use in women when they were under the age of 30
‡
      
 
Never  3·43 (1·55-9·69) 14 2·74 (1·90-4·21) 11 
0·757 0·0116 0·0028 
Several times per week 7·71 (4·74-7·77) 5 3·07 (2·75-4·52) 4 
Daily 8·35 (3·19-24·87) 31 4·34 (2·67-6·42) 34 
Several times per day 12·25 (8·56-14·68) 4 2·51 (1·86-4·86) 3 
UCP use during last 5 years before BC diagnosis in cases / during last 5 years before interview in controls
‡
  
Never  3·09 (1·55-5·34) 10 3·32 (1·90-4·21) 10 
0·916 0·0079 0·0054 
Several times per week 7·71 (3·27-7·77) 5 3·07 (2·55-5·86) 6 
Daily 7·69 (3·59-18·41) 32 3·96 (2·54-5·99) 31 
Several times per day 12·90 (3·83-16·15) 7 4·86 (2·51-10·23) 5 
 
Table 4b: Tumor located in other quadrants  
Median (IQR) of Al
3+ 
concentration
†
  3·94 (1·90-10·92) 45  3·77 (2·47-5·78) 52   0·2642 
UCP use in women when they were under the age of 30
‡
      
 
Never  4·63 (1·90-8·82) 14 2·74 (1·90-4·21) 11 
0·017 0·3457 0·3558 
Several times per week 11·16 (7·08-16·18) 4 3·07 (2·75-4·52) 4 
Daily 3·48 (1·24-8·99) 22 4·34 (2·67-6·42) 34 
Several times per day 3·62 (3·39-12·91) 5 2·51 (1·86-4·86) 3 
UCP use during last 5 years before BC diagnosis in cases / during last 5 years before interview in controls
‡
  
Never  4·63 (1·90-7·91) 10 3·32 (1·90-4·21) 10 
0·015 0·1316 0·3731 
Several times per week 10·92 (3·23-11·40) 5 3·07 (2·55-5·86) 6 
Daily 3·94 (1·51-9·76) 25 3·96 (2·54-5·99) 31 
Several times per day 3·62 (3·39-12·91) 5 4·86 (2·51-10·23) 5 
†
 Independent samples t-test with log10(x+1) transformed data. 
‡
 Three-way analysis of variance with log10(x+1) transformed data. Repeated aluminum measurements at three 
different sampling locations (upper outer, mammilla and lower inner breast quadrant) were considered as within -
subject factor in the ANOVA. P-values < 0.0125 (Bonferroni correction for multiple comparisons) indicate 
statistical significance. 
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